Results 31 to 40 of about 70,021 (330)
Metoprolol responding uveitis [PDF]
Eye, 2004 Noninfectious uveitis is usually managed by topical and systemic corticosteroids and in refractory cases by immunosuppressive drugs.To describe a patient with noninfectious anterior and posterior uveitis, refractory to corticosteroids, and immunosuppressive therapy, which responded to systemic metoprolol.A 49-year-old patient was treated for 3 years ...
Y Kassif, Shimon Rumelt, Uri Rehany
openaire +3 more sources
Interaction of Palmitic Acid with Metoprolol Succinate at the Binding Sites of Bovine Serum Albumin [PDF]
Advanced Pharmaceutical Bulletin, 2014 Purpose: The aim of this study was to characterize the binding profile as well as to notify the interaction of palmitic acid with metoprolol succinate at its binding site on albumin.
Mashiur Rahman +3 more
doaj +1 more source
Metoprolol for the Prevention of Acute Exacerbations of COPD.
New England Journal of Medicine, 2019 BACKGROUND Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.
M. Dransfield +34 more
semanticscholar +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2020 Recent CYP2D6 phenotype standardization efforts by CYP2D6 activity score (AS) are based on limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Using data from two independent clinical trials of metoprolol, we compared metoprolol PK and PD across ...
Cameron D Thomas +24 more
semanticscholar +1 more source
Effect of hesperetin on the pharmacokinetics of metoprolol succinate in rats
Future Journal of Pharmaceutical Sciences, 2023 Background Metoprolol is a substrate of CYP3A4, 2B6, CYP2D6, CYP2C9, and p-glycoprotein (p-gp). Hesperetin was reported as an inhibitor of cytochrome P-450 (CYP) enzymes and p-gp. The objective of this study was to investigate the effect of hesperetin on
Ravindra Babu Pingili +5 more
doaj +1 more source
Pharmaceutics, 2020 The beta-blocker metoprolol (the sixth most commonly prescribed drug in the USA in 2017) is subject to considerable drug–gene interaction (DGI) effects caused by genetic variations of the CYP2D6 gene. CYP2D6 poor metabolizers (5.7% of US population) show
Simeon Rüdesheim +6 more
semanticscholar +1 more source
The Journal of Headache and Pain, 2017 Background Beta-blockers are a first choice migraine preventive medication. So far it is unknown how they exert their therapeutic effect in migraine. To this end we examined the neural effect of metoprolol on trigeminal pain processing in 19 migraine ...
Julia M. Hebestreit, Arne May
doaj +1 more source
Mitochondrial Disorder Aggravated by Metoprolol [PDF]
Case Reports in Pediatrics, 2016 Beta-adrenergic blocking agents or beta-blockers are a class of medications used to treat cardiac arrhythmias and systemic hypertension. In therapeutic dosages, they have known adverse outcomes that can include muscular fatigue and cramping, dizziness, and dyspnea. In patients with mitochondrial disease, these effects can be amplified.
Cheryl Samuels +4 more
openaire +4 more sources
Beta-blocker under-use in COPD patients [PDF]
, 2017 Background: Cardiovascular (CVS) comorbidities are common in COPD and contribute significantly to morbidity and mortality, especially following acute exacerbations of COPD (AECOPD).
Lavender, Melanie +4 more
core +2 more sources
Revista Colombiana de Cardiología, 2012 realizar una evaluación de costo-efectividad del uso de metoprolol succinato frente a metoprolol tartrato y carvedilol en el tratamiento de pacientes con insuficiencia cardiaca congestiva e hipertensión arterial en Colombia, desde la perspectiva del ...
Martín Romero, MD., MSc. +1 more
doaj +1 more source